Status:
COMPLETED
Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
Lead Sponsor:
Louisiana State University and A&M College
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Dependence
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This project tests the feasibility and utility of a novel, integrated approach to treatment of patients with cannabis use disorder (CUD) and anxiety disorders.
Detailed Description
Cannabis use disorder (CUD) is the most common illicit substance dependence and people with CUD are highly vulnerable to anxiety disorders. The co-occurrence of anxiety disorders among those with CUD ...
Eligibility Criteria
Inclusion
- Diagnosis of cannabis use disorder
- An additional diagnosis of an anxiety disorder
- Patient reports that at least some of his/her cannabis use is aimed at reducing anxiety and/or for social facilitation.
- Patient reports that cannabis is his/her substance of choice for anxiety management.
- Concurrent use of psychotropic medications (e.g., selective serotonin reuptake inhibitors) is permitted as long as patients have been on a stable dose for at least three months prior to entering the study and they are willing to remain stable on their medication for the duration of treatment.
- Age between 18 and 65 years.
- English language fluency.
- Willing and able to provide written informed consent.
Exclusion
- Alcohol or illicit substance (non-cannabis) dependence.
- Cannabis use behavior sufficiently uncontrolled that proper participation in study protocol would likely be disrupted.
- History of schizophrenia, bipolar disorder, or organic brain syndrome.
- Prominent suicidal ideation with intent that is judged to be clinically significant.
- Mental retardation or another pervasive developmental disability (e.g., Asperger's Disorder).
- Sufficiently socially unstable as to preclude completion of study requirements (e.g., homeless).
- Prior simultaneous cognitive behavioral treatment for cannabis dependence and anxiety disorders.
- Legally mandated to receive substance abuse treatment.
- Report of current participation in or intent to participate in an additional (i.e., treatments other than MET-CBT or MET alone) anxiety or substance abuse treatment method during the course of the study.
- Unwilling to maintain stable dose of regularly-dosed medications during the study
- Unwilling to cease PRN (pro re nata or "as needed") use of benzodiazepines or other fast-acting anxiolytics prior to entrance into social situations.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01875796
Start Date
June 1 2013
Last Update
August 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Louisiana State University Anxiety & Addictive Behaviors Clinic
Baton Rouge, Louisiana, United States, 70803